Research programme: pain therapeutics - Eli Lilly/RaQualia Pharma

Drug Profile

Research programme: pain therapeutics - Eli Lilly/RaQualia Pharma

Latest Information Update: 02 Jul 2014

Price : $50

At a glance

  • Originator Eli Lilly; RaQualia Pharma
  • Class Analgesics
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 27 Jun 2014 Discontinued for Pain in USA (unspecified route)
  • 27 Jun 2014 RaQualia Pharma and Eli Lilly conclude the term of their research agreement for the development of pain therapeutics
  • 19 Jul 2013 RaQualia Pharma and Eli Lilly agree to extend their research agreement for the development of pain therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top